Infectious Diseases News and Research

RSS

Researchers show how microbiota protects against type 1 diabetes development

Our bodies have ten times the amount of microbes than human cells. This set of bacteria is called microbiota. In some instances, bacteria known as pathogens can cause infectious diseases. However, these micro-organisms can also protect us from certain diseases. Researchers from Inserm, Paris Descartes University and the CNRS (French National Centre for Scientific Research), through collaboration with teams from China and Sweden, have recently shown how microbiota protects against the development of type 1 diabetes.

7 Aug 2015

BD reports adjusted revenues of $3.133 billion for third fiscal quarter 2015

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly adjusted revenues of $3.133 billion for the third fiscal quarter ended June 30, 2015, an increase of 45.2 percent over the prior-year period as reported, or 55.6 percent on a currency-neutral basis. On a comparable, currency-neutral basis, adjusted revenues grew 2.4 percent. As reported, revenues were $3.120 billion.

From BD (Becton, Dickinson and Company) 6 Aug 2015

Children increase parents’ risk for viral infection

The BIG LoVE (Utah Better Identification of Germs-Longitudinal Viral Epidemiology) study, led by scientists at the University of Utah School of Medicine, finds that each bundle of joy puts the entire household at increased risk for infection with viruses that cause colds, flu, and other respiratory illnesses.

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Rice University scientists identify genetic mechanism that allows bacteria to resist antibiotics

Rice University scientists are developing strategies to keep germs from evolving resistance to antibiotics by heading them off at the pass.

5 Aug 2015

Coordinated, two-part approach could help reduce hospital-acquired infections

By coordinating with state health departments and communicating with each other about patients with C. difficile and antibiotic-resistant infections, hospitals, long-term acute-care facilities and nursing homes could reduce the number of such hospital-acquired infections (HAIs) by an estimated 619,000 cases in the next five years, a new Centers for Disease Control 9 (CDC)-led report has found.

5 Aug 2015

Armada, UMass Medical School partner to enhance ArmadaOne Specialty Pharmacy Workflow Platform

Armada Health Care has partnered with University of Massachusetts Medical School's Clinical Pharmacy Services business unit to provide enhancements and support regarding clinical protocols and therapy interventions within the ArmadaOne Specialty Pharmacy Workflow Platform.

4 Aug 2015

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.

4 Aug 2015

California Initiative to Advance Precision Medicine selects two demonstration projects

Two demonstration projects that aim to yield quick results for patients have been selected by the new California Initiative to Advance Precision Medicine, a public-private effort launched by Governor Edmund G. Brown Jr.

4 Aug 2015

New article proposes creation of $2 billion global vaccine-development fund to prevent infectious diseases

Ebola is a preventable disease, and yet a safe and effective vaccine has not been deployed. As with many vaccines, financial barriers persist: pharmaceutical companies see high costs with limited market potential, and government support is lacking. But there may be a solution to this vaccine crisis with the ability to save at-risk populations, according to a perspective piece written by physicians based at Princeton University, University of Pennsylvania and the Wellcome Trust.

4 Aug 2015

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern Medicine scientists have received a five-year, $17.5 million grant from the National Institutes of Health for an interdisciplinary project that aims to invent, develop and test an implantable drug delivery system to protect high-risk individuals from HIV infection for up to a year at a time.

4 Aug 2015

Penn Medicine devises new approach to develop vaccines against lethal diseases

Researchers at the Perelman School of Medicine at the University of Pennsylvania have devised an entirely new approach to vaccines - creating immunity without vaccination.

4 Aug 2015

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University.

4 Aug 2015

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa.

4 Aug 2015

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC.

3 Aug 2015

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.

3 Aug 2015

Guinea Phase III trial shows VSV-EBOV vaccine highly effective against Ebola

Results from an interim analysis of the Guinea Phase III efficacy vaccine trial show that VSV-EBOV (Merck, Sharp & Dohme) is highly effective against Ebola.

31 Jul 2015

Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract, part of the body's microbiome.

31 Jul 2015

IUPUI researchers receive NIH grant to study effect of depression treatment on cardiovascular disease

Indiana University-Purdue University Indianapolis researchers led by Jesse Stewart of the School of Science, have received a $2.6 million grant from the National Institutes of Health to conduct the first randomized controlled trial to determine whether depression treatment can help prevent the development of cardiovascular disease.

31 Jul 2015

Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Roche today announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the U.S. Food and Drug Administration, as a companion diagnostic test for AZD9291, an AstraZeneca investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation.

30 Jul 2015

Infectious Diseases News and Research

Researchers show how microbiota protects against type 1 diabetes development

BD reports adjusted revenues of $3.133 billion for third fiscal quarter 2015

Children increase parents’ risk for viral infection

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Rice University scientists identify genetic mechanism that allows bacteria to resist antibiotics

Coordinated, two-part approach could help reduce hospital-acquired infections

Armada, UMass Medical School partner to enhance ArmadaOne Specialty Pharmacy Workflow Platform

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

California Initiative to Advance Precision Medicine selects two demonstration projects

New article proposes creation of $2 billion global vaccine-development fund to prevent infectious diseases

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Penn Medicine devises new approach to develop vaccines against lethal diseases

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Guinea Phase III trial shows VSV-EBOV vaccine highly effective against Ebola

Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

IUPUI researchers receive NIH grant to study effect of depression treatment on cardiovascular disease

Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Industry Focus eBook - Infectious Diseases (3rd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News